6HV1.F Rezolute, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 6HV1.F undervalued?
Graham numberThe Graham number of Rezolute, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rezolute, Inc. fundamental analysis
No fundamental analysis for Rezolute, Inc. yet.
Rezolute, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, In…
Full company profileFinancial statements of Rezolute, Inc. are not available yet.
Rezolute, Inc. dividends
Rezolute, Inc. has not paid dividends in the last 4 fiscal years.
Who owns Rezolute, Inc.
- Insiders 10.03%
- Institutions 89.97%
- Public & others 0.00%
- Free float 60.8M
Rezolute, Inc. company profile
- Company name
- Rezolute, Inc.
- Ticker
- 6HV1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Fiscal year end
- June
- Address
- 275 Shoreline Drive, Redwood City, CA, United States, 94065
- Phone
- 650 206 4507
- Website
- rezolutebio.com
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc. management
10- Mr. Nevan Charles Elam J.D.Founder, CEO & Acting Chairman of the Board · born 1967
- Mr. Daron G. Evans M.B.A., M.S.Chief Financial & Business Officer · born 1974
- Dr. Brian Kenneth Roberts M.D.Chief Medical Officer · born 1975
- Dr. Sunil Karnawat M.B.A., Ph.D.Chief Commercial Officer · born 1967
- Mr. Michael R. DeperroSenior VP & Head of Operations
- Dr. Davelyn Eaves Hood M.B.A., M.D.Director and Head of Scientific & Patient Affairs
- Ms. Melissa QuinnSenior Director of People and Culture
- Ms. Robyn SweinhartVP & Head of Quality
- Ms. Erin O'BoyleSenior VP & Head of Clinical Operations
- Ms. Susan Stewart J.D., L.L.M.Chief Regulatory Officer · born 1961